• Overexpression of these two genes was associated with poor tumor response to anthracycline treatment in a neoadjuvant chemotherapy trial in women with primary breast cancer. (bioseek.eu)
  • Neoadjuvant chemotherapy (NAC) is one of the standard care regimens for patients with resectable early-stage breast cancer. (biomedcentral.com)
  • We investigated whether the use of ACEI/ARBs affects the clinical outcomes of primary breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy. (jcancer.org)
  • We included 1449 patients with diagnosis of invasive primary breast cancer diagnosed at the MD Anderson Cancer Center between 1995 and 2007 who underwent neoadjuvant chemotherapy. (jcancer.org)
  • No differences in pCR and survival outcomes were seen between ACEI/ARB users and non-users among breast cancer patients receiving neoadjuvant chemotherapy. (jcancer.org)
  • The aim of this study is to evaluate the prognostic factors of the group who received neoadjuvant chemotherapy with a taxane-anthracycline combination regimen. (kjco.org)
  • We retrospectively analyzed for locally advanced breast cancer patients who received neoadjuvant chemotherapy with adjuvant extension with taxane-anthracycline combination regimen. (kjco.org)
  • 101 patients received neoadjuvant chemotherapy with docetaxel and doxorubicin, 46 patients received with epirubicin and paclitaxel. (kjco.org)
  • The adjuvant chemotherapy regimen was adjusted when the response to neoadjuvant chemotherapy was in disease progression. (kjco.org)
  • In order to predict an oncologic outcome from locally advanced breast cancer patients who are treated with neoadjuvant chemotherapy with taxane-anthracycline based regimen, we can use pathologic complete response, an early response to neoadjuvant chemotherapy. (kjco.org)
  • Neoadjuvant chemotherapy (NC) is a standard therapy for locally advanced breast cancer patients [ 1 ]. (kjco.org)
  • Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Prospektive, randomisierte Phase-II Studie zur intensivie. (trialstracker.net)
  • Combining some of these neoadjuvant approaches with standard-of-care chemotherapy or radiotherapy appears to "sensitize" tumor cells to treatment. (cancerbiomed.org)
  • In addition, a deeper characterization of immune infiltrates, including the presence of a high number of cytotoxic (CD8 + ) TILs or a high CD8 + /FOXP3 + ratio, is able to define TNBC patients with a better prognosis following neoadjuvant chemotherapy [ 6 ]. (biomedcentral.com)
  • Approximately 60% of the enrolled patients (451 for each treatment arm) experienced relapse after prior adjuvant/neoadjuvant treatment, while 37% presented with de novo stage IV disease. (biomedcentral.com)
  • When given as neoadjuvant treatment before surgery, THP is usually given four times, once every 3 weeks. (lbbc.org)
  • Neoadjuvant Chemotherapy in High-Risk Soft-Tissue Sarcoma: A New Standard? (ascopost.com)
  • For the first time, a randomized trial has provided good evidence to support the use of neoadjuvant chemotherapy for treatment of high-risk soft-tissue sarcoma of the extremities or trunk wall. (ascopost.com)
  • 1 But the findings of the study were surprising, because neoadjuvant chemotherapy with. (ascopost.com)
  • Among breast cancer patients, human epidermal growth factor receptor-2 (HER2)-positive patients account for about 15-20.0%[ 3 , 4 ]. (biomedcentral.com)
  • HER2/neu (also called ERB B2 ) is the gene that encodes the human epidermal growth factor receptor type 2. (cancerquest.org)
  • By using integrated genomics, we identified a small number of overexpressed and amplified genes from chromosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. (bioseek.eu)
  • Using integrated genomics, we identified a small number of over-expressed and amplified genes from chromosome 8q22 significantly associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. (bioseek.eu)
  • More effective treatments are needed for breast cancer that becomes locally advanced or metastatic. (roche.com)
  • An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination with Epirubicin, Cisplatin and Capecitabine (ECX) versus ECX Chemotherapy alone in Subjects with Locally Advanced Gastr. (trialstracker.net)
  • Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin (FLOT) in combination with Trastuzumab in patients with HER2-positive, locally advanced resectable. (trialstracker.net)
  • 11 ] demonstrated a substantial overall survival (OS) benefit in patients with PD-L1-positive (PD-L1 + ) metastatic or inoperable locally advanced TNBC through the addition of the anti-PD-L1 agent atezolizumab to first-line chemotherapy with nab-paclitaxel. (biomedcentral.com)
  • Some of the new approaches depend on tumor biology and aim specifically to inhibit tumor growth and metastasis by targeting the tumor microenvironment or vasculature (leaving normal cells unaffected) or focusing on specific protein or signal transduction pathways. (medscape.com)
  • The following recommendations are based on tumor/node/metastasis (TNM)-based stages. (medscape.com)
  • Generally, tumor size and axillary lymph node metastasis status are the most important prognostic factors for breast cancer patients. (kjco.org)
  • Thus, angiogenesis is a necessary and required step for transition from a small harmless cluster of cells to a large tumour and is also required for the spread of a tumour, invasion and/or metastasis. (biomedcentral.com)
  • This test filters circulating tumor cells from a patient's blood sample and gives a numerical probability of metastasis for colon, breast, prostate and ovarian adenocarcinomas. (dunphynunley.com)
  • The current study was performed to examine the feasibility, safety and immunogenicity of adding P10s-PADRE to standard-of-care chemotherapy in HR+/HER2− early-stage breast cancer patients. (oncotarget.com)
  • Targeted molecular therapy, like therapy with monoclonal antibodies, gene therapy, and other therapies, has limited or nonexistent side effects on normal cells of the body, unlike present modalities such as surgery, chemotherapy, and radiotherapy. (medscape.com)
  • Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. (drugs.com)
  • 40 mg/m 2 on day 1 and 30 mg/m 2 on day 8 every 28 days (as part of the VCAP-AMP-VECP multiagent chemotherapy regimen) for 6 cycles (Tsukasaki 2007). (medilib.ir)
  • After curative surgery, adjuvant chemotherapy with the same regimen was performed. (kjco.org)
  • Tumor-infiltrating lymphocytes (TIL) were assessed by hematoxylin/eosin stain and quantitative fluorescence. (aacrjournals.org)
  • The percentage of tumor-infiltrating lymphocytes (TILs) was determined. (oncotarget.com)
  • Targeted molecular therapy against EGFR has shown promise as an adjuvant therapy in preliminary studies in several solid tumors, including head and neck cancer. (medscape.com)
  • Preclinical success has led to a profusion of clinical trials on LB100 adjuvant therapies, including a phase I trial in extensive-stage small-cell lung cancer, a phase I/II trial in myelodysplastic syndrome, a phase II trial in recurrent glioblastoma, and a completed phase I trial assessing the safety of LB100 and docetaxel in various relapsed solid tumors. (cancerbiomed.org)
  • Carboplatin is an alternative for cisplatin in the treatment of urothelial cancers. (shengsci.com)
  • Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer. (shengsci.com)
  • abstract: PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). (shengsci.com)
  • furthermore, owing to both its in vitro synergy with other cytotoxic agents, and its tolerability as a single agent, it is amenable to combination with traditional chemothera-peutic drugs, eg, doxorubicin and cisplatin. (kanker-actueel.nl)
  • MATERIALS AND METHODS:This study included a total of 47 consecutive Japanese mCRPC patients treated with cabazitaxel and assessed the prognostic significance of cabazitaxel, focusing on patient age and the correlation of efficacy between docetaxel and cabazitaxel. (shengsci.com)
  • This phase II study combined elotuzumab (Elo) with carfilzomib, lenalidomide, and dexamethasone (KRd) for treatment of MM in first relapse with the aim of improving efficacy. (bvsalud.org)
  • The predictive efficacy of both models decreased and the difference was greater in advanced HER2 + patients, which means the HBN model had higher robustness and more stable predictive performance in the subgroup. (biomedcentral.com)
  • He, H. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. (eurekaselect.com)
  • Secondary acute myelogenous leukemia and myelodysplastic syndrome occur at a higher incidence in patients treated with anthracyclines, including doxorubicin. (medilib.ir)
  • Core needle biopsy (CNB) specimens and resected tumors were obtained from all patients before and after NAC, respectively. (biomedcentral.com)
  • Therefore, it would be advantageous to identify patients with chemosensitive tumors before initiating NAC, to avoid potential therapy-related complications and an inappropriate delay of surgical treatment. (biomedcentral.com)
  • Liquid biopsy: The genomic alterations of solid cancers can be identified by evaluating circulating tumor DNA (ctDNA) in the blood This procedure is used more in patients who cannot undergo traditional biopsy, but can also be performed in other patients to gather more evidence for management. (medscape.com)
  • A study by Fogh et al of induction chemoradiotherapy followed by surgery, a strategy that is widely used in treating esophageal cancer, found that perioperative morbidity and mortality with this approach was not significantly different in patients aged 70 years or older compared with younger patients. (medscape.com)
  • The discovery and development of novel treatments that harness the patient's immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. (biomedcentral.com)
  • However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. (biomedcentral.com)
  • These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. (biomedcentral.com)
  • The excision of the clipped node (92.0%), use of dual tracer (73.2%), and axillary US (65.9%) after treatment were the most important variables considered by respondents, to increase the accuracy of SLNB in cN + patients. (unav.edu)
  • The laparoscopic approach for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (L-CRS + HIPEC) in highly selected patients was previously reported from the PSOGI registry with a demonstrable reduction in length of stay and post-operative morbidity. (unav.edu)
  • An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX alone for Second-line Treatment of Patients with Metastatic Clororectal Cancer. (trialstracker.net)
  • Given the lack of effective treatments in this subtype of breast cancer, several efforts have been conducted in recent years to increase the therapeutic opportunities for TNBC patients. (biomedcentral.com)
  • BACKGROUND:The correlation of the oncological outcomes of docetaxel and cabazitaxel in Japanese metastatic castration-resistant prostate cancer (mCRPC) patients has not been unclear. (shengsci.com)
  • A 30% PSA response to cabazitaxel was achieved in 13 (46.4%) and 7 (36.8%) patients with and without that to docetaxel, respectively. (shengsci.com)
  • A 30% PSA response to cabazitaxel was achieved in 5 (16.6%) and 7 (41.2%) patients who had treated with less than 10 cycles docetaxel or 10 ≦ cycles, respectively. (shengsci.com)
  • CONCLUSION:These results indicate that the introduction of cabazitaxel for Japanese mCRPC patients could result in oncological outcomes without any association with patient's age and the profiles of previous docetaxel therapy. (shengsci.com)
  • abstract: PURPOSE:M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. (shengsci.com)
  • INTRODUCTION: Treatment of patients with multiple myeloma (MM) in first relapse remains a challenge. (bvsalud.org)
  • METHODS: Enrolled patients received Elo-KRd induction for 4 cycles, and Elo-lenalidomide maintenance until progression. (bvsalud.org)
  • Finally, the late HER2 + patients(n = 395) was selected for subgroup analysis. (biomedcentral.com)
  • The follow-up time of breast cancer data with diagnosis in 2019 in the SEER database is less than two years, this study also used 1-year survival as the study outcome, to establish a predictive model to identify people with better and worse prognosis, especially people with a poorer prognosis, and to assist physicians in taking the best interventional treatment for patients promptly. (biomedcentral.com)
  • For patients with advanced non-small cell lung cancer (NSCLC) harboring the ALK gene rearrangement, ceritinib (Zykadia) provided longer progression-free survival than chemotherapy in patients previously treated with chemotherapy and crizotinib (Xalkori), but gastrointestinal toxicity was. (ascopost.com)
  • Unfortunately for the development of the drug, during the course of its phase III development, the combination of pemetrexed and a platinum derivative emerged as the standard first-line treatment for MMe patients in. (kanker-actueel.nl)
  • Breast cancer patients diagnosed with HR+/HER2- tumors face a persistent risk of distant recurrence long after completion of their treatment. (oncotarget.com)
  • Strategies to induce anti-tumor immune responses could complement standard-of-care therapies for these patients. (oncotarget.com)
  • SiRNA-mediated knockdown of either of two of these genes, the antiapoptotic gene YWHAZ and a lysosomal gene LAPTM4B, sensitized tumor cells to anthracyclines, and overexpression of either of the genes induced anthracycline resistance. (bioseek.eu)
  • Two of these genes, the anti-apoptotic gene YWHAZ , and LAPTM4B , a novel lysosomal gene, sensitized tumor cells to anthracyclines when either was depleted by siRNA knockdown and induced drug resistance when either was over-expressed. (bioseek.eu)
  • Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. (bioseek.eu)
  • Adjuvant chemotherapy for breast cancer after surgery has effectively lowered metastatic recurrence rates. (bioseek.eu)
  • Even though considerable treatment progress and more effective therapies have been achieved over the past years, recurrence in the long-term and undesired side effects are still the main drawbacks of current clinical protocols. (oaepublish.com)
  • Even though there has been a progress achieved in the development of more effective therapies against cancer, over the past years, recurrence of tumour growth and metastatic spread in the long-term is a common event. (oaepublish.com)
  • Treatment of acute lymphoblastic leukemia (ALL) requires both systemically and locally directed therapies to prevent central nervous system (CNS) recurrence. (bvsalud.org)
  • Various techniques have been developed for targeting cancer cells: gene therapy, monoclonal antibodies (MAbs), antibody toxin conjugates, small-molecule inhibitors, antisense molecules, and tumor vaccines. (medscape.com)
  • Of note, an increased carbohydrate uptake and/or induction of death receptors of cancer cells was exploited to develop glycoconjugates that potentially induce cellular stress, ROS and apoptosis. (degruyter.com)
  • Plants are natural reservoirs of novel compounds and provide a promising therapeutic approach for treatment of cancer. (researchsquare.com)
  • Naturally occurring compounds from plants known as phytochemicals, fill in as indispensable assets for novel medications and are likewise rich sources for cancer treatment. (researchsquare.com)
  • However, a considerable proportion of women suffer recurrent cancer at distant metastatic sites despite adjuvant treatment. (bioseek.eu)
  • Breast cancer (BC) is the most frequent oncologic cause of death among women and the improvement of its treatments is compelling. (mdpi.com)
  • Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-MacGregor M. Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. (jcancer.org)
  • Eralp Y, Aydıner A,Kizir A,Kaytan E,Oral EN,Topuz E, "Resectable thymoma: treatment outcome and prognostic factors in the late adolescent and adult age group," Cancer Investigation 21(5),737-43 (2003). (yesimeralp.com)
  • Indications for single-agent therapy, preferred second-line therapy, subsequent therapy, relapsed or refractory therapy, pediatric and adult treatment, and limitations of use are all addressed within each section of specific cancer. (ibx.com)
  • Targeting these pathways via small molecule inhibitors or monoclonal antibodies has been a focus of more contemporary approaches to cancer treatment. (cancerbiomed.org)
  • Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. (biomedcentral.com)
  • We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. (biomedcentral.com)
  • This review focusses on clinical aspects of treatment of breast cancer with monoclonal antibodies, and tyrosine kinase and mammalian target of rapamycin (mTOR) inhibitors. (biomedcentral.com)
  • The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought breast cancer into the immunotherapy era. (biomedcentral.com)
  • Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast carcinomas and is associated with earlier age of onset, aggressive clinical course, and dismal prognosis compared to hormone receptor- and HER2-positive breast carcinomas [ 1 ]. (biomedcentral.com)
  • New and relevant evidence on the implementation of immune checkpoint-based treatments in TNBC has emerged over the last year, with the results of the IMpassion130 trial bringing breast cancer into the immunotherapy era. (biomedcentral.com)
  • A study by Fogh et al examined the use of induction chemoradiotherapy followed by surgery a strategy that is widely used in treating esophageal cancer. (medscape.com)
  • These limitations of conventional cancer therapies prompted the use of nanomedicine, the medical application of nanotechnology, to provide more effective and safer cancer treatment. (oaepublish.com)
  • Cancer resistance can either exist before treatment (intrinsic) or can be generated after therapy (acquired) [ 4 ] . (oaepublish.com)
  • Closer understanding of the mechanisms involved in drug resistance is needed in order to achieve better outcomes in cancer treatment. (oaepublish.com)
  • Cancer cells are masters in finding a way to resist the treatment designed to kill them. (oaepublish.com)
  • Docetaxel works by damaging the structure or the "skeleton" that supports cancer cells. (lbbc.org)
  • Trastuzumab attaches to HER2 proteins on the surface of HER2-positive cancer cells and blocks the signals that cause cancer cells to multiply. (lbbc.org)
  • THP is also used to treat metastatic HER2-positive breast cancer. (lbbc.org)
  • The results not only help the practitioner and patient choose an effective combination of therapies, but also helps them understand which cancer genes (oncogenes) are blocked by which treatments. (dunphynunley.com)
  • It is the same for the treatment and regulation of cancer. (dunphynunley.com)
  • Genomic assays have had a powerful influence on the management of early-stage breast cancer, particularly estrogen receptor-positive tumors. (ascopost.com)
  • The mainstay of adjuvant treatment for early-stage, hormone receptor-positive breast cancer has been endocrine therapy, either with tamoxifen and. (ascopost.com)
  • Statistics help us understand who is at risk for breast cancer, where more resources are needed, and how efforts to improve screening , treatment, and care are working. (lbbc.org)
  • Alsatinib Tablet is used in the treatment of blood cancer (chronic myeloid leukaemia). (varunmedicals.com)
  • In particular, the present invention provides methods for enhancing the effectiveness of chemotherapy by inducing differential stress resistance in normal cells and cancer cells via short-term starvation, cell growth inhibitors, or reduced caloric or glucose intake. (justia.com)
  • Until recently, the treatment of cancer has been largely focused on the development of therapeutic agents or techniques that kill cancer cells. (justia.com)
  • In another aspect, the invention features methods of contacting a cancer cell with a chemotherapy agent and methods of increasing resistance of a non-cancer cell to a chemotherapy agent. (justia.com)
  • In cultured primary fibroblasts and cancer cells, the chemotherapeutic drug doxorubicin causes mtDNA damage and release, which leads to cGAS STING dependent ISG activation. (regenerativemedicine.net)
  • Lavasanifar, A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. (eurekaselect.com)
  • This task can be accomplished by replacing tumor suppressor genes that have been lost or mutated, selectively inserting genes that produce cytotoxic substances, or modifying the immune system to destroy the tumor cells. (medscape.com)
  • This is in contrast with tumor suppressor genes which must BOTH be defective to lead to abnormal cell division. (cancerquest.org)
  • Second-line and subsequent therapy may involve single agents (eg, taxanes) or molecular therapy, such as ramucirumab to target vascular endothelial growth factor (VEGF) receptor or trastuzumab for metastatic adenocarcinoma that overexpresses HER2. (medscape.com)
  • It attaches to the HER2 protein in a different way from trastuzumab, so the two medicines work together well. (lbbc.org)
  • If your doctor recommends you stop docetaxel due to side effects, you may still be able to continue treatment with pertuzumab and trastuzumab. (lbbc.org)
  • For early and some locoregional cancers, surgery is the primary treatment. (medscape.com)
  • Doxorubicin (Dox), a non-selective class I anthracycline antibiotic, is a potent chemotherapeutic agent which is used for the treatment of numerous cancers [ 1 ]. (oncotarget.com)
  • Although PP2A has historically been identified as a tumor suppressor, inhibition of PP2A has paradoxically demonstrated potential as a therapeutic target for various cancers. (cancerbiomed.org)
  • For chemotherapy, two-drug cytotoxic regimens that include a platinum agent are generally preferred for first-line therapy. (medscape.com)
  • Doxorubicin (Dox) is a cytotoxic drug widely incorporated in various chemotherapy protocols. (oncotarget.com)
  • The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents. (justia.com)
  • Because chemotherapy affects cell division, both normal and cancerous cells are susceptible to the cytotoxic effects of chemotherapeutic agents. (justia.com)
  • ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may have anti-tumor properties. (jcancer.org)
  • There is a growing body of evidence to suggest that ACEIs might have anti-tumor properties[ 2 , 3 ]. (jcancer.org)
  • Antibody response was superior in schedule C where 3 weekly immunizations preceded the first dose of chemotherapy. (oncotarget.com)
  • Identification of the genes crucial for tumor response to specific chemotherapy drugs is a challenge but is necessary to improve outcomes. (bioseek.eu)
  • Overexpression of these two genes may predict anthracycline resistance and influence selection of chemotherapy. (bioseek.eu)
  • This first category also includes genes that contribute to tumor growth by inhibiting cell death. (cancerquest.org)
  • The genes in the second group are called tumor suppressors. (cancerquest.org)
  • Hier de conclusie van deze review en daaronder een studie abstract met ranpirnasse uit 2002 met bijzonder goede resultaten op de mediane overlevingstijd. (kanker-actueel.nl)
  • They have complementary mechanisms to hinder the carcinogenic process by searching free radicals, inhibiting survival and multiplication of malignant cells, as well as reducing invasiveness and angiogenesis of tumors. (researchsquare.com)
  • Angiotensin II is now regarded as a tumor growth promoter via angiogenesis from activation of the VEGF pathway[ 4 - 6 ]. (jcancer.org)
  • The inhibition of angiogenesis is emerging as a new, attractive therapeutic approach to control tumour progression [ 1 ]. (biomedcentral.com)
  • Many studies have reported that there are no differences in the oncologic outcomes between NC and adjuvant chemotherapy [ 2 ]. (kjco.org)
  • 1. Resistance of tumors to multiple chemotherapeutic agents is often due to the MDR (Multiple Drug Resistance) gene. (examyear.com)
  • It also has severe limitations on the dosage of chemotherapeutic agents that can be administered to a patient, thus, limiting the effective range of chemotherapy. (justia.com)
  • By making normal cells more resistant to chemotherapeutic agents, a patient's tolerance for cytotoxicity is improved, which, in turn, also improves the effectiveness of chemotherapy. (justia.com)
  • EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3. (trialstracker.net)
  • The HER (erbB) family of transmembrane receptor tyrosine kinases is one of the cytostatic targets in tumor cell growth and survival. (medscape.com)
  • The 5 year disease-free survival (DFS) per tumor origin was: 94% for PMP-LG, 85% for PMP-HG, 100% for benign multicyst peritoneal mesothelioma (MPM), 37.4% for colonic origin, and 54%(at 3 years) for ovarian origin. (unav.edu)
  • Tumor PD-L1 protein expression may predict response to drugs targeting this pathway. (aacrjournals.org)
  • The past decade has seen the discovery and development of novel treatments that harness the patient's immune system and prevent immune escape due to increased understanding of the tumor immune environment. (biomedcentral.com)
  • Dano, K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. (nature.com)
  • When the NC is performed, tumors and axillary lymph nodes are down staged, resulting in the loss of traditional prognostic factors [ 6 ]. (kjco.org)
  • Table 1 summarises the results from phase II trials utilizing bevacizumab in combination with chemotherapy, many of which are still preliminary. (biomedcentral.com)
  • CONCLUSION: A short course of Elo-KRd induction followed by Elo-lenalidomide maintenance demonstrated activity in predominantly lenalidomide-refractory and / or high-risk MM. The results with this well-tolerated combination are comparable to other contemporary approved triplet combinations. (bvsalud.org)
  • Thus, while waiting the final results of the above study, it appears clear that ranpirnase may find its niche (in combination with doxorubicin) for second-line therapy of MMe (Pavlakis and Vogelzang 2006) where, at present, no standard of care exists. (kanker-actueel.nl)
  • The combination therapy is safe and immunogenic with treatment schedule C being immunologically promising. (oncotarget.com)
  • The taxanes have been used to improve treatment outcomes alone or with anthracycline [ 7 - 9 ]. (kjco.org)
  • If a doctor treats a systemic infection without first doing a culture and sensitivity test to determine which bacteria is involved and which antibiotics the bacteria is sensitive to, then he might prescribe the wrong treatment and thereby strengthen the infection. (dunphynunley.com)
  • The current conventional modalities (surgery, radiation, chemotherapy) are nonselective and can cause damage to normal tissue. (medscape.com)
  • Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting. (medilib.ir)
  • In clinical practice, a key challenge for generating TIL products is the accessibility, quantity, and quality of tumor tissue in the era of neo-adjuvant therapy. (biomedcentral.com)
  • Acid-labile linkage, catering for the pH difference between tumor cells and normal tissue, has been utilized to release drugs at tumor tissue. (eurekaselect.com)
  • Other prognostic factors are required for making a difference from adjuvant chemotherapy. (kjco.org)
  • The aim of our review is to present recent advances in TNBC treatment and to discuss open issues in order to better define potential future directions for immunotherapy in TNBC. (biomedcentral.com)
  • There were no treatment-related deaths during LR-ESHAP cycles. (bvsalud.org)
  • Univariate and multivariate analyses revealed that there were no significant correlation of patient age (p = 0.537), the response to prior docetaxel therapy (p = 0.339) or cycles of docetaxel therapy (p = 0.379) with shorter OS. (shengsci.com)
  • T4b tumors involving pericardium, pleura, diaphragm are also potentially resectable. (medscape.com)
  • At present, a European lab offers a blood test which filters and isolates circulating tumor cells (a.k.a. micrometastatic cells) from a patient's blood, genetically fingerprints them, then pharmacogenetically tests the cells for the effectiveness of various medical therapies. (dunphynunley.com)
  • PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-line Treatment of Subjects With A Phase 3 Clinical Trial Comparing Infusional 5 Fluorouracil, Leucovorin, and Oxaliplatin. (med-abstracts.com)
  • Open biopsy is contraindicated due to: пїЅ Risk of seeding of tumour in neoplastic circumstances medications that raise blood sugar [url=https://livrobranco.gov.ao/rx-pills/buy-biltricide-online-in-usa/]generic 600mg biltricide with amex[/url]. (ehd.org)